Dyne Therapeutics, Inc. (DYN) Form 8-K — Jul 29, 2026
Dyne Therapeutics reported a second quarter net loss of $178.6 million, or $1.08 per share, compared to a net loss of $110.9 million, or $0.97 per share, in the prior year period. The increase in loss was driven by higher research and development expenses of $152.2 million, primarily due to increased manufacturing and clinical trial activities for its lead programs. The company announced that the FDA accepted its Biologics License Application (BLA) for z-rostudirsen for Priority Review, with a PDUFA target action date of January 21, 2027.
Key figures
- Cash Position
- 898475000
- Research And Development
- 152169000
- General And Administrative
- 29492000
- Pdufa Date
- 2027-01-21
- Cash Runway
- Q2 2028
- Net Proceeds
- 405000000
- Gross Proceeds
- 431000000
- Offering Price
- 20.5
- Offering Shares
- 21045000
- Debt Facility Expansion
- 400000000
Price after filing
Close on the filing date to close N calendar days later (from $25.10). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.